The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

Inhibitors of PI3K/Akt signaling are being actively developed for tumor therapy owing to the frequent mutational activation of the PI3K-Akt-mTORC1 pathway in many cancers, including glioblastomas (GBMs). NVP-BEZ235 is a novel and potent dual PI3K/mTOR inhibitor that is currently in phase 1/2 clinica...

Full description

Bibliographic Details
Main Authors: Bipasha Mukherjee, Nozomi Tomimatsu, Kaushik Amancherla, Cristel V. Camacho, Nandini Pichamoorthy, Sandeep Burma
Format: Article
Language:English
Published: Elsevier 2012-01-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558612800765